SG10201406805RA - Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one - Google Patents

Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Info

Publication number: SG10201406805RA
Authority: SG; Singapore
Prior art keywords: azepino; polymorphs; indol; methylamino; tetrahydro
Prior art date: 2010-02-12

Application number

SG10201406805RA

Inventor

Patricia Ann Basford

Anthony Michael Campeta

Adam Gillmore

Matthew Cameron Jones

Robert Walton

Eleftherios Kougoulos

Suman Luthra

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-12

Filing date

2011-02-10

Publication date

2014-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43859823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201406805R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-10 Application filed by Pfizer filed Critical Pfizer

2014-11-27 Publication of SG10201406805RA publication Critical patent/SG10201406805RA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG10201406805RA 2010-02-12 2011-02-10 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one SG10201406805RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30427710P	2010-02-12	2010-02-12

Publications (1)

Publication Number	Publication Date
SG10201406805RA true SG10201406805RA (en)	2014-11-27

Family

ID=43859823

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201406805RA SG10201406805RA (en)	2010-02-12	2011-02-10	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
SG2012052171A SG182533A1 (en)	2010-02-12	2011-02-10	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG2012052171A SG182533A1 (en)	2010-02-12	2011-02-10	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Country Status (32)

Country	Link
US (5)	US8754072B2 (en)
EP (4)	EP4166558A1 (en)
JP (6)	JP5745283B2 (en)
KR (2)	KR102108226B1 (en)
CN (2)	CN102884066B (en)
AR (2)	AR080164A1 (en)
AU (1)	AU2011213944B2 (en)
BR (1)	BR112012019050B1 (en)
CA (2)	CA2787881C (en)
CY (3)	CY1118319T1 (en)
DK (2)	DK2534153T4 (en)
ES (2)	ES2607806T5 (en)
FI (1)	FI2534153T4 (en)
HK (1)	HK1176617A1 (en)
HR (2)	HRP20161742T4 (en)
HU (3)	HUE030969T2 (en)
IL (1)	IL220921B (en)
LT (3)	LT3150610T (en)
LU (1)	LUC00093I2 (en)
MX (1)	MX343383B (en)
NL (1)	NL300958I2 (en)
NO (1)	NO2018039I1 (en)
NZ (1)	NZ601445A (en)
PL (2)	PL2534153T3 (en)
PT (2)	PT2534153T (en)
RS (2)	RS55487B2 (en)
RU (1)	RU2570198C2 (en)
SG (2)	SG10201406805RA (en)
SI (2)	SI3150610T1 (en)
SM (1)	SMT201600462B (en)
TW (1)	TWI545123B (en)
WO (1)	WO2011098971A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS55487B2 (en)	2010-02-12	2024-06-28	Pfizer	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
TW201516636A (en) *	2013-10-22	2015-05-01	Hon Hai Prec Ind Co Ltd	Electronic device and power supply method thereof
WO2016028689A1 (en) *	2014-08-22	2016-02-25	Clovis Oncology, Inc.	High dosage strength tablets of rucaparib
US20190276405A1 (en) *	2016-05-16	2019-09-12	Pulmagen Therapeutics (Asthma) Limited	Crystal of quinoline derivative
DE102016218772A1 (en) *	2016-09-28	2018-03-29	Bruker Biospin Gmbh	Improved tempering of an NMR MAS rotor
KR20190110579A (en)	2017-01-24	2019-09-30	아시아 케미컬 인더스트리스 리미티드	Solid phase form of leucaprip and leucaprip salt
CN109651377B (en) *	2017-10-12	2020-10-20	成都海创药业有限公司	Compound for treating cancer and application thereof
WO2019086509A1 (en)	2017-11-03	2019-05-09	Sandoz Ag	Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
WO2019115000A1 (en) *	2017-12-15	2019-06-20	Advitech Advisory And Technologies Sa	Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en)	2017-12-28	2019-07-04	Mylan Laboratories Ltd	Methods and intermediates for preparing rucaparib
JP7356450B2 (en)	2018-01-05	2023-10-04	サイブレクサ１・インコーポレイテッド	Compounds, compositions, and methods for the treatment of diseases involving acidic or hypoxic diseased tissue
US10442813B2 (en)	2018-01-30	2019-10-15	RK Pharma Solutions LLC	Polymorphs of rucaparib camsylate and methods of making same
WO2019207498A1 (en) *	2018-04-25	2019-10-31	Biophore India Pharmaceuticals Pvt. Ltd	Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
WO2019207596A1 (en)	2018-04-25	2019-10-31	Mylan Laboratories Limited	Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
CN108743557A (en) *	2018-06-27	2018-11-06	李莉	A kind of phosphoric acid Rui Kapabu soft capsules and preparation method thereof
CN109111454A (en) *	2018-08-01	2019-01-01	宁波金未生物科技有限公司	A kind of Rui Kapabu S- camsilate
CN111217818A (en) *	2018-11-27	2020-06-02	台耀化学股份有限公司	Crystal of lucapanib camphorsulfonate, and method for producing tricyclic compound, lucapanib and its camphorsulfonate crystal
WO2020113500A1 (en) *	2018-12-06	2020-06-11	上海诚妙医药科技有限公司	Rucaparib camsylate, preparation method therefor, and uses thereof
JP2022541749A (en)	2019-07-10	2022-09-27	サイブレクサ２，インコーポレイテッド	Peptide conjugates of cytotoxins as therapeutic agents
CA3146385A1 (en)	2019-07-10	2021-01-14	Cybrexa 3, Inc.	Peptide conjugates of microtubule-targeting agents as therapeutics
CN111004244A (en) *	2019-12-27	2020-04-14	重庆市碚圣医药科技股份有限公司	Synthetic method of Ruipafebu camphorsulfonate
WO2021156140A1 (en)	2020-02-03	2021-08-12	Sandoz Ag	Polymorph of rucaparib mesylate
US20210330665A1 (en) *	2020-04-24	2021-10-28	Astrazeneca Ab	Pharmaceutical formulations
CA3176206A1 (en)	2020-04-28	2021-11-04	Debnath Bhuniya	Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
JP2023533982A (en)	2020-07-10	2023-08-07	ザリージェンツオブザユニバーシティオブミシガン	GAS41 inhibitor and method of use thereof
WO2022015557A1 (en)	2020-07-14	2022-01-20	Assia Chemical Industries Ltd	Solid state forms of rucaparib salts
WO2022090938A1 (en)	2020-10-31	2022-05-05	Rhizen Pharmaceuticals Ag	Phthalazinone derivatives useful as parp inhibitors
JP2024515338A (en)	2021-04-08	2024-04-09	ライゼンファーマシューティカルズアーゲー	Inhibitors of poly(ADP-ribose) polymerase
WO2023137060A1 (en)	2022-01-11	2023-07-20	Assia Chemical Industries Ltd.	Solid state forms of rucaparib tosylate
WO2023152754A1 (en) *	2022-02-08	2023-08-17	Sawant, Mohit Manikrao	Crystalline form of rosuvastatin allyl ester
WO2024118070A1 (en) *	2022-11-30	2024-06-06	Ideaya Biosciences, Inc.	2-oxoquinazoline crystalline forms

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4489011A (en)	1983-05-16	1984-12-18	Merrell Dow Pharmaceuticals Inc.	Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
DE4125292A1 (en) *	1991-07-31	1993-02-04	Kali Chemie Pharma Gmbh	6-OXO-AZEPINOINDOL COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR MANUFACTURE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1514934B1 (en)	1992-02-06	2008-12-31	Novartis Vaccines and Diagnostics, Inc.	Biosynthetic binding protein for cancer marker
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
DE69519751T2 (en)	1995-04-20	2001-04-19	Pfizer Inc., New York	ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF MMP AND TNF
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en)	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
ATE225343T1 (en)	1995-12-20	2002-10-15	Hoffmann La Roche	MATRIX METALLOPROTEASE INHIBITORS
ATE211134T1 (en)	1996-03-05	2002-01-15		4-ANILINOQUINAZOLINE DERIVATIVES
JP3195756B2 (en)	1996-07-04	2001-08-06	公子吉水	Lubrication auxiliary
EP0818442A3 (en)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
ES2191187T3 (en)	1996-07-13	2003-09-01	Glaxo Group Ltd	BICYCLE HETEROAROMATIC COMPOUNDS AS INHIBITORS OF PROTEIN TIROSIN-QUINASA.
ES2186908T3 (en)	1996-07-13	2003-05-16	Glaxo Group Ltd	HETEROCICICLES CONDENSED COMPOUNDS AS INHIBITORS OF PPROTEINA-TIROSINA-QUINASAS.
DK0923585T3 (en)	1996-07-18	2002-07-01	Pfizer	Phosphinate-based inhibitors of matrix metalloproteinases
SK21499A3 (en)	1996-08-23	2000-05-16	Pfizer	Arylsulfonylamino hydroxamic acid derivatives
ID18494A (en)	1996-10-02	1998-04-16	Novartis Ag	PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
CA2277100C (en)	1997-01-06	2005-11-22	Pfizer Inc.	Cyclic sulfone derivatives
EA002594B1 (en)	1997-02-03	2002-06-27	Пфайзер Продактс Инк.	Arylsulfonylamino hydroxamic acid derivatives
EP0966438A1 (en)	1997-02-07	1999-12-29	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
KR20000070923A (en)	1997-02-11	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	Arylsulfonyl hydroxamic acid derivatives
ATE292623T1 (en)	1997-05-07	2005-04-15	Sugen Inc	2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ATIVITY
CA2291709A1 (en)	1997-05-30	1998-12-03	Merck & Co., Inc.	Novel angiogenesis inhibitors
US5835420A (en)	1997-06-27	1998-11-10	Aplus Flash Technology, Inc.	Node-precise voltage regulation for a MOS memory system
EA002490B1 (en)	1997-08-08	2002-06-27	Пфайзер Продактс Инк.	Aryloxyarylsulfonylamino hydroxamic acid derivatives
EP1005470B1 (en)	1997-08-22	2007-08-01	AstraZeneca AB	Oxindolylquinazoline derivatives as angiogenesis inhibitors
CA2303830A1 (en)	1997-09-26	1999-04-08	Merck & Co., Inc.	Novel angiogenesis inhibitors
EP1028964A1 (en)	1997-11-11	2000-08-23	Pfizer Products Inc.	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
RS49779B (en)	1998-01-12	2008-06-05	Glaxo Group Limited,	Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
JP4462654B2 (en)	1998-03-26	2010-05-12	ソニー株式会社	Video material selection device and video material selection method
PA8469401A1 (en)	1998-04-10	2000-05-24	Pfizer Prod Inc	BICYCLE DERIVATIVES OF HYDROXAMIC ACID
PA8469501A1 (en)	1998-04-10	2000-09-29	Pfizer Prod Inc	HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
AR018408A1 (en)	1998-05-29	2001-11-14	Sugen Inc	PIRROL SUBSTITUTE COMPOUND 2-INDOLINONE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, USE OF SUCH COMPOSITE IN A 'IN VIVO' METHOD AND ITS USE FOR THE PREPARATION OF SUCH COMPOSITION
UA60365C2 (en)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
ATE260255T1 (en)	1998-11-05	2004-03-15	Pfizer Prod Inc	5-OXO-PYRROLIDINE-2-CARBONIC ACID HYDROXAMIDE DERIVATIVES
BR9916518A (en)	1998-12-23	2002-01-29	Searle & Co	A method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and a combination comprising a cyclooxygenase-2 inhibitor and one or more antineoplastic agents.
US6649645B1 (en)	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
RO121778B1 (en)	1999-01-11	2008-04-30	Agouron Pharmaceuticals, Inc.	Tricyclic inhibitors of poly(adp-ribose) polymerase
KR100452491B1 (en)	2001-03-29	2004-10-12	한미약품 주식회사	A novel crystalline amlodipine camsylate and a preparing method thereof
KR20040011751A (en)	2002-07-30	2004-02-11	씨제이 주식회사	An organic acid salt of amlodipine
CN1726208A (en) †	2002-12-19	2006-01-25	辉瑞产品公司	Complexes of E-2-methoxy-N-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
WO2004087713A1 (en)	2003-03-31	2004-10-14	Pfizer Inc.	Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
WO2005012305A2 (en)	2003-07-25	2005-02-10	Cancer Research Technology Limited	Tricyclic parp inhibitors
KR20070046183A (en)	2004-09-22	2007-05-02	화이자 인코포레이티드	Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
ATE452895T1 (en)	2004-09-22	2010-01-15	Pfizer	METHOD FOR PRODUCING POLY(ADPRIBOSE)POLYMERASE INHIBITORS
CN101384264B (en) *	2004-09-22	2012-03-14	辉瑞大药厂	Therapeutic combinations comprising poly (adp-ribose) polymerases inhibitor
KR100853601B1 (en)	2004-09-22	2008-08-22	화이자 인코포레이티드	Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-?4-??methylamino?methyl?phenyl?-1,3,4,5-tetrahydro-6h-azepino?5,4,3-cd?indol-6-one
GB0502509D0 (en)	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
KR20070111534A (en) *	2005-02-23	2007-11-21	테바 파마슈티컬 인더스트리즈 리미티드	Rasagiline formulations of improved content uniformity
BRPI0621789A2 (en) *	2006-07-05	2012-05-02	Teva Pharma	memantine pharmaceutical compositions
KR100843401B1 (en)	2006-12-04	2008-07-04	씨제이제일제당 (주)	Crystalline S---amlodipine camsylate anhydrous and preparation method thereof
CN101573328B (en) *	2006-12-06	2014-04-02	科内图斯医药公司	Crystalline forms of ( 3 s ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaniwyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
WO2008114114A2 (en) †	2007-03-16	2008-09-25	Pfizer Products Inc.	Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
EP2065385A1 (en)	2007-11-28	2009-06-03	Laboratorios SALVAT, S.A.	Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
JP2011506315A (en) *	2007-12-05	2011-03-03	バイアル−ポルテラアンドシーエー，エス．エー．	New salts and crystal forms
KR20090060674A (en)	2007-12-10	2009-06-15	씨제이제일제당 (주)	Crystalline sulfonic acid salt of ziprasidone, a process for the preparation thereof, and a pharmaceutical composition comprising the same
KR101653548B1 (en) †	2008-01-08	2016-09-02	머크 샤프 앤드 돔 리미티드	2-4-3--3--2--7- Pharmaceutically acceptable salts of 2-4-3-piperidin-3-ylphenyl-2H-indazole-7-carboxamide
EP2387539B1 (en)	2009-01-17	2019-12-11	Boomerang Systems. Inc.	Automated storage system with transport vehicle
RS55487B2 (en)	2010-02-12	2024-06-28	Pfizer	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CN103930931A (en)	2011-09-23	2014-07-16	金泰克斯公司	Systems and methods for rear view mirror displays
MX2014007691A (en)	2011-12-26	2015-02-10	Wintech Polymer Ltd	Polybutylene terephthalate resin pellets, and production method for said polybutylene terephthalate resin pellets.
US9384339B2 (en)	2012-01-13	2016-07-05	Telecommunication Systems, Inc.	Authenticating cloud computing enabling secure services
US9672526B2 (en)	2012-03-13	2017-06-06	American Express Travel Related Services Company, Inc.	Systems and methods for tailoring marketing
KR101984831B1 (en)	2013-01-31	2019-05-31	삼성전자 주식회사	Semiconductor package
CN103309115B (en)	2013-05-30	2016-03-23	京东方科技集团股份有限公司	Color electrophoresis display panel and manufacture method, display device
US9501163B2 (en)	2014-05-06	2016-11-22	Symbol Technologies, Llc	Apparatus and method for activating a trigger mechanism
US10884952B2 (en)	2016-09-30	2021-01-05	Intel Corporation	Enforcing memory operand types using protection keys
JP6943759B2 (en)	2017-12-28	2021-10-06	株式会社東海理化電機製作所	Shift device

2011
- 2011-02-10 RS RS20161117A patent/RS55487B2/en unknown
- 2011-02-10 DK DK11708094.5T patent/DK2534153T4/en active
- 2011-02-10 EP EP22199074.0A patent/EP4166558A1/en active Pending
- 2011-02-10 LT LT16183844T patent/LT3150610T/en unknown
- 2011-02-10 PT PT117080945T patent/PT2534153T/en unknown
- 2011-02-10 DK DK16183844T patent/DK3150610T3/en active
- 2011-02-10 PL PL11708094T patent/PL2534153T3/en unknown
- 2011-02-10 EP EP19178840.5A patent/EP3597651A1/en not_active Withdrawn
- 2011-02-10 RU RU2012138892/04A patent/RU2570198C2/en active
- 2011-02-10 CA CA2787881A patent/CA2787881C/en active Active
- 2011-02-10 JP JP2011026718A patent/JP5745283B2/en active Active
- 2011-02-10 CA CA3024216A patent/CA3024216C/en active Active
- 2011-02-10 SG SG10201406805RA patent/SG10201406805RA/en unknown
- 2011-02-10 AU AU2011213944A patent/AU2011213944B2/en active Active
- 2011-02-10 HU HUE11708094A patent/HUE030969T2/en unknown
- 2011-02-10 NZ NZ601445A patent/NZ601445A/en unknown
- 2011-02-10 SI SI201131808T patent/SI3150610T1/en unknown
- 2011-02-10 WO PCT/IB2011/050571 patent/WO2011098971A1/en active Application Filing
- 2011-02-10 ES ES11708094T patent/ES2607806T5/en active Active
- 2011-02-10 PL PL16183844T patent/PL3150610T3/en unknown
- 2011-02-10 MX MX2012008911A patent/MX343383B/en active IP Right Grant
- 2011-02-10 HU HUE16183844A patent/HUE047248T2/en unknown
- 2011-02-10 SG SG2012052171A patent/SG182533A1/en unknown
- 2011-02-10 BR BR112012019050-4A patent/BR112012019050B1/en not_active IP Right Cessation
- 2011-02-10 KR KR1020197005968A patent/KR102108226B1/en active IP Right Grant
- 2011-02-10 SI SI201131051T patent/SI2534153T2/en unknown
- 2011-02-10 CN CN201180009237.0A patent/CN102884066B/en active Active
- 2011-02-10 RS RS20191394A patent/RS59494B1/en unknown
- 2011-02-10 PT PT161838446T patent/PT3150610T/en unknown
- 2011-02-10 EP EP16183844.6A patent/EP3150610B1/en active Active
- 2011-02-10 HR HRP20161742TT patent/HRP20161742T4/en unknown
- 2011-02-10 US US13/522,549 patent/US8754072B2/en active Active
- 2011-02-10 KR KR1020127023813A patent/KR20120127495A/en active Search and Examination
- 2011-02-10 CN CN201410818193.1A patent/CN104876937B/en active Active
- 2011-02-10 LT LTEP11708094.5T patent/LT2534153T/en unknown
- 2011-02-10 EP EP11708094.5A patent/EP2534153B2/en active Active
- 2011-02-10 ES ES16183844T patent/ES2753748T3/en active Active
- 2011-02-11 AR ARP110100427A patent/AR080164A1/en not_active Application Discontinuation
- 2011-02-11 TW TW100104676A patent/TWI545123B/en active
2012
- 2012-07-12 IL IL220921A patent/IL220921B/en active IP Right Grant
2013
- 2013-03-28 HK HK13103915.1A patent/HK1176617A1/en unknown
2014
- 2014-05-08 US US14/272,589 patent/US9045487B2/en active Active
2015
- 2015-04-21 JP JP2015086722A patent/JP6013551B2/en active Active
- 2015-04-28 US US14/698,463 patent/US9861638B2/en active Active
2016
- 2016-09-21 JP JP2016183846A patent/JP6371350B2/en active Active
- 2016-12-13 CY CY20161101288T patent/CY1118319T1/en unknown
- 2016-12-21 SM SM201600462T patent/SMT201600462B/en unknown
2017
- 2017-08-16 AR ARP170102290A patent/AR109356A2/en unknown
- 2017-12-06 US US15/833,073 patent/US10278974B2/en active Active
2018
- 2018-07-12 JP JP2018132270A patent/JP6640931B2/en active Active
- 2018-11-13 CY CY2018031C patent/CY2018031I2/en unknown
- 2018-11-13 LU LU00093C patent/LUC00093I2/fr unknown
- 2018-11-14 HU HUS1800046C patent/HUS1800046I1/en unknown
- 2018-11-15 LT LTPA2018517C patent/LTC2534153I2/en unknown
- 2018-11-15 NO NO2018039C patent/NO2018039I1/en unknown
- 2018-11-16 FI FIEP11708094.5T patent/FI2534153T4/en active
- 2018-11-19 NL NL300958C patent/NL300958I2/en unknown
2019
- 2019-02-28 US US16/288,615 patent/US20200000821A1/en not_active Abandoned
- 2019-10-25 HR HRP20191944TT patent/HRP20191944T1/en unknown
- 2019-10-31 CY CY20191101132T patent/CY1122218T1/en unknown
- 2019-12-26 JP JP2019235421A patent/JP2020050671A/en not_active Withdrawn
2021
- 2021-05-06 JP JP2021078485A patent/JP2021107460A/en active Pending

Also Published As

Publication number	Publication date
KR20120127495A (en)	2012-11-21
EP2534153A1 (en)	2012-12-19
JP2011168587A (en)	2011-09-01
CN104876937A (en)	2015-09-02
NZ601445A (en)	2014-08-29
SG182533A1 (en)	2012-08-30
US20150238504A1 (en)	2015-08-27
SI3150610T1 (en)	2019-12-31
US9045487B2 (en)	2015-06-02
ES2607806T3 (en)	2017-04-04
HRP20161742T1 (en)	2017-02-24
CY2018031I1 (en)	2019-11-27
SMT201600462B (en)	2017-03-08
EP3150610A1 (en)	2017-04-05
AR109356A2 (en)	2018-11-21
CN102884066A (en)	2013-01-16
DK2534153T4 (en)	2024-06-03
CN102884066B (en)	2015-01-07
US9861638B2 (en)	2018-01-09
CA3024216C (en)	2021-03-30
RU2570198C2 (en)	2015-12-10
PT3150610T (en)	2019-11-11
MX343383B (en)	2016-11-03
LTC2534153I2 (en)	2021-03-10
LTPA2018517I1 (en)	2018-12-10
LT2534153T (en)	2016-12-12
JP2021107460A (en)	2021-07-29
EP3150610B1 (en)	2019-07-31
SI2534153T2 (en)	2024-07-31
EP2534153B1 (en)	2016-09-21
HUE047248T2 (en)	2020-04-28
JP6013551B2 (en)	2016-10-25
IL220921B (en)	2020-03-31
RS55487B2 (en)	2024-06-28
EP2534153B2 (en)	2024-05-22
CN104876937B (en)	2017-07-28
US8754072B2 (en)	2014-06-17
PL3150610T3 (en)	2020-02-28
EP3597651A1 (en)	2020-01-22
NL300958I2 (en)	2018-12-19
AU2011213944A1 (en)	2012-08-09
AR080164A1 (en)	2012-03-21
CA3024216A1 (en)	2011-08-18
CY1122218T1 (en)	2020-11-25
MX2012008911A (en)	2012-08-15
FI2534153T4 (en)	2024-06-26
RS55487B1 (en)	2017-04-28
HUS1800046I1 (en)	2018-12-28
EP4166558A1 (en)	2023-04-19
ES2607806T5 (en)	2024-10-07
JP2016216507A (en)	2016-12-22
TWI545123B (en)	2016-08-11
JP5745283B2 (en)	2015-07-08
KR102108226B1 (en)	2020-05-08
LUC00093I1 (en)	2018-11-15
NO2018039I1 (en)	2018-11-15
BR112012019050A2 (en)	2016-09-13
ES2753748T3 (en)	2020-04-14
PT2534153T (en)	2016-12-27
LT3150610T (en)	2019-11-11
JP2018199679A (en)	2018-12-20
DK3150610T3 (en)	2019-11-04
WO2011098971A1 (en)	2011-08-18
RU2012138892A (en)	2014-03-20
DK2534153T3 (en)	2017-01-09
LUC00093I2 (en)	2019-12-24
CA2787881C (en)	2019-01-08
CY2018031I2 (en)	2019-11-27
US20140243318A1 (en)	2014-08-28
BR112012019050A8 (en)	2017-12-26
CA2787881A1 (en)	2011-08-18
CY1118319T1 (en)	2017-06-28
PL2534153T3 (en)	2017-08-31
JP2015131858A (en)	2015-07-23
US20200000821A1 (en)	2020-01-02
TW201144316A (en)	2011-12-16
HK1176617A1 (en)	2013-08-02
BR112012019050B1 (en)	2021-12-21
HUE030969T2 (en)	2017-06-28
JP6371350B2 (en)	2018-08-08
HRP20161742T4 (en)	2024-07-05
RS59494B1 (en)	2019-12-31
HRP20191944T1 (en)	2020-01-24
AU2011213944B2 (en)	2014-10-02
JP6640931B2 (en)	2020-02-05
US20120302550A1 (en)	2012-11-29
US20180092925A1 (en)	2018-04-05
US10278974B2 (en)	2019-05-07
JP2020050671A (en)	2020-04-02
SI2534153T1 (en)	2017-01-31
KR20190026043A (en)	2019-03-12

Publication	Publication Date	Title
HUS1800046I1 (en)	2018-12-28	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1257363A1 (en)	2019-10-18	Pyrrolopyrimidine derivatives for use in the inhibition of polymerase
EP2649060A4 (en)	2014-07-09	Process for the preparation of benzimidazole derivatives and its salts
EP2244712A4 (en)	2011-08-03	In vivo studies of crystalline forms of meloxicam
IL220154A0 (en)	2012-07-31	Novel pyrimidine compounds as mtor and pi3k inhibitors
EP2530079A4 (en)	2013-06-19	Phenyl c-glucoside derivatives, preparation methods and uses thereof
SI2260029T1 (en)	2015-01-30	Preparation of morpholine derivatives
IL215865B (en)	2018-01-31	Formulation of meloxicam
EP2701504A4 (en)	2014-09-10	Derivatives of sulindac, use thereof and preparation thereof
SI2331098T1 (en)	2018-10-30	Methods for the administration of iloperidone
ZA201008860B (en)	2016-03-30	Pharmacokinetics of iontophorectic sumatriptan administration
ZA201101821B (en)	2012-01-25	1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin deases
GB2464854B (en)	2011-11-09	Process for the preparation of risperidone
EP2581375A4 (en)	2014-02-19	Improved methods for the preparation of quinoxaline derivatives
ZA201100319B (en)	2012-07-25	An article of furniture
PL391018A1 (en)	2011-10-24	Cysteines derivative salts and process for the preparation of cysteines derivative salts
GB0801288D0 (en)	2008-03-05	Use of compounds for preparing anti-tuberculosis agents
UA21094S (en)	2010-11-25	SET OF UPHOLSTERED FURNITURE "LUXURY"
GB0807168D0 (en)	2008-05-21	Moulding of articles
PL391562A1 (en)	2012-01-02	New aromatic compounds derivatives of vinylphenyl-arylen and process for the preparation thereof
PL391563A1 (en)	2012-01-02	New aromatic compounds derivatives of vinylphenyl-arylen and process for the preparation thereof
PL393037A1 (en)	2012-06-04	Process for the preparation of benzoxazole derivatives
GB0821710D0 (en)	2008-12-31	Derivatives of dihydroindolone